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Mutations Conferring Aminoglycoside and Spectinomycin Resistance
in Borrelia burgdorferi
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We have isolated and characterized in vitro mutants of the Lyme disease agent Borrelia burgdorferi that are
resistant to spectinomycin, kanamycin, gentamicin, or streptomycin, antibiotics that target the small subunit
of the ribosome. 16S rRNA mutations A1185G and C1186U, homologous to Escherichia coli nucleotides A1191
and C1192, conferred >2,200-fold and 1,300-fold resistance to spectinomycin, respectively. A 16S rRNA
A1402G mutation, homologous to E. coli A1408, conferred >90-fold resistance to kanamycin and >240-fold
resistance to gentamicin. Two mutations were identified in the gene for ribosomal protein S12, at a site
homologous to E. coli residue Lys-87, in mutants selected in streptomycin. Substitutions at codon 88, K88R and
K88E, conferred 7-fold resistance and 10-fold resistance, respectively, to streptomycin on B. burgdorferi. The
16S rRNA A1185G and C1186U mutations, associated with spectinomycin resistance, appeared in a population
of B. burgdorferi parental strain B31 at a high frequency of 6  106. These spectinomycin-resistant mutants
successfully competed with the wild-type strain during 100 generations of coculture in vitro. The aminoglyco-
side-resistant mutants appeared at a frequency of 3  109 to 1 107 in a population and were unable to
compete with wild-type strain B31 after 100 generations. This is the first description of mutations in the B.
burgdorferi ribosome that confer resistance to antibiotics. These results have implications for the evolution of
antibiotic resistance, because the 16S rRNA mutations conferring spectinomycin resistance have no significant
fitness cost in vitro, and for the development of new selectable markers.
The spirochete Borrelia burgdorferi is a tick-borne pathogen
that causes Lyme disease (62). Only a few antibiotics are avail-
able for clinical therapy of Lyme disease; the choice of new
treatments depends on the pharmacodynamic interactions of
the antimicrobial agent with the spirochete (30) and the fre-
quency of mutations conferring resistance. In addition, only a
few molecular tools are available for genetic manipulation of
B. burgdorferi (53); the choice of new selectable markers, which
is currently limited to antibiotic resistance (9, 16, 18, 56, 58),
also depends on the mutation frequency. A high mutation rate
conferring resistance to an antibiotic or a high frequency in the
population of organisms resistant to the antibiotic interferes
with selection. Further complicating the molecular genetics of
B. burgdorferi is its unusual genome, which comprises a 910-kb
linear chromosome as well as several linear and circular plas-
mids (2, 19). The chromosome contains two copies of the 23S
and 5S rRNA genes and a single copy of the 16S rRNA gene
(21, 22, 59). The secondary structure and sequence of the B.
burgdorferi 16S rRNA (Fig. 1) are similar to those of other
bacteria, including Escherichia coli and Thermus thermophilus,
and to those of eukaryotic chloroplast 16S rRNA found in
Chlamydomonas reinhardtii and Nicotiana tabacum (11). Be-
cause the 16S rRNA gene is present in only one copy in B.
burgdorferi, a single mutational event in the 16S rRNA gene
can confer resistance to any one of several antibiotics that
target the small ribosomal subunit.
Many antibiotics that target ribosomes, such as spectinomy-
cin and the aminoglycosides, either prevent translocation of
tRNAs during translation or cause errors in selecting cognate
tRNAs (3, 10, 12, 14, 50). Spectinomycin targets the 30S ribo-
somal subunit of many gram-negative bacteria, including E.
coli (3, 8, 10, 67). Spectinomycin blocks elongation of the
polypeptide during protein synthesis by binding to helix 34 of
the 16S rRNA and apparently preventing the translocation of
the peptidyl tRNA from the A-site to the P-site (3, 12). E. coli
and other organisms have been shown to be resistant to spec-
tinomycin when nucleotide C1192 or its cross-helix partner
G1064, in helix 34 of the 16S rRNA, is mutated (5, 10, 40, 47,
60). Mutations at sites 1191 and 1193 in the chloroplast 16S
rRNA of the eukaryotic organisms C. reinhardtii and N. tabacum
confer resistance to spectinomycin as well (28, 65).
Kanamycin and gentamicin bind to helix 44 of the 16S rRNA
and interfere with translational accuracy by increasing the af-
finity for noncognate tRNA selection (14, 15, 50, 51). Foot-
printing studies have demonstrated that resistance in E. coli
results from decreased binding affinity of kanamycin or genta-
micin to helix 44 upon mutation of site U1406 or A1408 in 16S
rRNA (15, 43, 50, 51). Kanamycin and gentamicin resistance in
Mycobacterium species have been mapped to mutations at ho-
mologous sites (49, 64).
Streptomycin also disrupts translational accuracy by increas-
ing the affinity for noncognate tRNA (31, 32). This error-
inducing activity is promoted by the formation of hydrogen
bonds between streptomycin and several sites in 16S rRNA
and ribosomal protein S12 (12, 61). Single mutations in the 16S
rRNA or the S12 gene, rpsL, in E. coli have been shown to
confer resistance to streptomycin (6, 20, 24, 39, 42, 46, 63).
Mutations at homologous sites in the 16S rRNA and the S12
* Corresponding author. Mailing address: Division of Biological Sci-
ences, The University of Montana, 32 Campus Dr., Missoula, MT
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protein also confer resistance to streptomycin in many other
organisms (17, 33, 41, 45, 61). An rpsL AAA-to-AGA mutation
in codon 88, resulting in a K88R substitution in the S12 pro-
tein, confers resistance to streptomycin in the spirochete Lep-
tospira biflexa (48).
There are only a few reports of antibiotic resistance in B.
burgdorferi, including one describing resistance to erythromy-
cin, which targets ribosomes in other bacteria (25, 57, 66). B.
burgdorferi strain N40 was shown to be 3,000 times more
resistant to the macrolide erythromycin than strain B31 (66).
Sequencing of the 23S rRNA gene, a common site for muta-
tions conferring erythromycin resistance in other bacteria, re-
vealed no mutations in B. burgdorferi strain N40 (66). Although
the mechanism of resistance has not been identified in strain
N40, erythromycin-resistant clones showed changes in colony
morphology on semisolid medium and lack of growth in liquid
medium, indicating that resistance may be due to changes in
metabolism (66).
We have identified five independent mutations in B. burg-
dorferi strain B31 conferring resistance to spectinomycin, kana-
mycin, gentamicin, or streptomycin. This study is the first to
identify ribosomal mutations and one of only three, to our
knowledge, in which genomic mutations have been associated
with antibiotic resistance in B. burgdorferi (25, 57). The high
frequency of spectinomycin-resistant mutants maintained in a
population of strain B31–A and their ability to compete in vitro
with wild-type cells imply that the antibiotic-resistant mutants
not only are fit for the environment in which they were selected
but also have maintained fitness in the absence of selection.
MATERIALS AND METHODS
Isolation and sequencing of antibiotic-resistant mutants. Borrelia burgdorferi
strain B31–A (9) was grown at 34°C in Barbour-Stoenner-Kelly (BSK)-H me-
dium (Sigma). To determine the frequency of antibiotic-resistant cells in the B.
burgdorferi population and to estimate the resistance levels of these strains, 107
or 108 cells (from a culture at 108 cells ml1) were plated in semisolid BSK
medium (54) with antibiotics (Sigma) at concentrations of 1.5, 6, or 30 g ml1
for spectinomycin, 40 g ml1 for kanamycin, 36 g ml1 for streptomycin, and
30 g ml1 for gentamicin. Kanamycin, gentamicin, and streptomycin plates with
the same antibiotic concentrations were also inoculated with 109 cells obtained
by concentrating cultures. The plates were incubated at 34°C for 11 to 14 days
before colonies appeared. Seven spectinomycin-resistant colonies, three kana-
mycin-resistant colonies, four streptomycin-resistant colonies, and one gentami-
cin-resistant colony were isolated from the plates and grown in 10 ml of BSK-H
medium containing the respective antibiotic; DNA was extracted as previously
described (57).
FIG. 1. Borrelia burgdorferi 16S rRNA secondary-structure model. Enlarged regions show point mutations that confer resistance to spectino-
mycin (A1185 and C1186) and kanamycin or gentamicin (A1402). (Adapted from http://www.rna.icmb.utexas.edu/ [11] with permission.)
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DNA encoding the 3 end of the 16S rRNA in the spectinomycin-, kanamycin-,
and gentamicin-resistant strains was amplified by PCR using primers 16S 40F
and 16S 659R (Table 1). The rpsE gene, which encodes the S5 protein, was also
amplified in the spectinomycin-resistant mutants using primers rpsE U322F and
rpsE 441R (Table 1). The rpsL gene, encoding protein S12, and the entire 16S
rRNA gene were amplified in streptomycin-resistant strains using primers rpsL
U106F and rpsG 58R and primers 16S U169F, 16S 40F, 16S 553F, 16S 659R, 16S
993R, 16S 1060F, 16S 1538R, BB425 3F, and BB426 288F, respectively (Table 1).
The amplified products were purified using a QIAquick PCR purification kit
(QIAGEN) and sequenced at the Murdock DNA Sequencing Facility (The
University of Montana).
Susceptibility and growth assays. Antibiotic susceptibility assays for parental
strain B31–A and a representative strain for each of the five mutants were
performed as previously described (18, 55). The concentration at which 50% of
growth is inhibited (IC50) was determined for spectinomycin, streptomycin, kana-
mycin, and gentamicin.
Growth was assayed by spectrophotometry as previously described (55) with
the following modifications. Cultures were inoculated with 106 cells of each strain
into 50 ml of BSK-H, and 10 ml of each culture was removed every 24 h. The
optical density at 600 nm was determined, and the doubling time was calculated
during the exponential-growth phase. A Student t test was performed to evaluate
the significance of the differences in doubling times between the wild type and
four of the mutants.
Competition assay. An in vitro competition assay between wild-type B31–A
and the mutant antibiotic-resistant strains, similar to that described by Moine
et al. (44), was performed. Cultures of B. burgdorferi strains B31–A, DCSPR3,
DCSPR6, DCSmR4, and DCKAN3 were grown, without selection, in 10 ml of
BSK-H to a density of 108 cells ml1. Approximately 105 cells of each strain were
added to 10 ml of BSK-H to formulate the following nine cultures: B31–A alone,
DCSPR3 alone, DCSPR6 alone, DCSmR4 alone, DCKAN3 alone, B31–A
plus DCSPR3, B31–A plus DCSPR6, B31–A plus DCSmR4, and B31–A plus
DCKAN3. The cultures were incubated for 96 h until a density of about 108 cells
ml1 was reached, and 105 cells were passaged into 10 ml of BSK-H. After 5 or
10 passages (20 or 40 days), which correspond to about 50 or 100 generations, 103
cells from each of the nine different cultures were plated on semisolid BSK
medium with and without the appropriate antibiotic (spectinomycin, streptomy-
cin, or kanamycin) to screen for the ratio of antibiotic-resistant colonies to total
colonies (antibiotic resistant plus wild type). In addition, 20 colonies were taken
from the B31–A-plus-DCSPR3 plate with no selection and 20 colonies were
taken from the B31–A-plus-DCSPR6 plate with no selection. Each of these
colonies was added to one of the wells in a 24-well culture dish containing 2 ml
of BSK-H with 30 g ml1 of spectinomycin. DCSPR3 or DCSPR6 mutants were
added to three of the wells for positive controls, and one of the wells, to which
no cells were added, served as a negative control. A color change in the BSK-H
medium (from red to yellow; caused by the decrease in pH) was used to deter-
mine if the well was positive or negative for spectinomycin-resistant mutants.
RESULTS
In a previous effort to develop a new selectable marker for
manipulating the B. burgdorferi genome, we discovered a high
frequency of background mutants in 1.5 g ml1 spectinomy-
cin, which precluded using this antibiotic for selection (18).
Several other bacteria with 16S rRNA mutations conferring
spectinomycin resistance have been identified, so we hypothe-
sized that B. burgdorferi strain B31–A may harbor a subpopu-
lation with a 16S rRNA mutation. The susceptibilities of wild-
type B31–A to spectinomycin, as well as to the aminoglycosides
kanamycin, gentamicin, and streptomycin, were determined
(Table 2) and found to be similar to our previously published
values (18).
Frequency and identification of spectinomycin-resistant
mutations. The frequency of the spectinomycin-resistant mu-
tants was determined by plating either 107 or 108 cells of B.
burgdorferi strain B31–A in 1.5 g ml1, 6.0 g ml1, or 30 g
ml1 of spectinomycin, concentrations 7-fold, 27-fold, or 136-
fold higher than the IC50, respectively, and colonies typically
appeared within 11 days. Each of these experiments yielded a
frequency of spectinomycin mutants in the B. burgdorferi pop-
ulation of about 6  106 (Table 3).
Spectinomycin-resistant mutations have been mapped to the
16S rRNA in other bacteria (3, 5, 12, 26, 40, 47, 60). Therefore,
we sequenced the 16S rRNA gene in seven spectinomycin-
resistant mutants to determine if similar mutations were re-
sponsible for resistance in B. burgdorferi. Three mutants, DC-
SPR5, DCSPR6, and DCSPR7, had an A1185G mutation in 16S
rRNA. The other four mutants, DCSPR1, DCSPR2, DCSPR3,
TABLE 1. Oligonucleotides used for sequencing the genes
encoding the 16S rRNA and the ribosomal
proteins S5 and S12
Oligonucleotide
name Gene Sequence
rpsE U322F rpsE (S5) 5-AATAAAGGACAAAATAGGG-3
rpsE 441R rpsE (S5) 5-CAAAACTAAATCAAATGCC-3
16S U169F 16S rRNA 5-AATGACCTAAAATTAAGTCTAA-3
16S 40F 16S rRNA 5-TTGTTACGACTTCACCCCCCTC-3
16S 553F 16S rRNA 5-TCAAGCCCTGGTAAGGTTCC-3
16S 659R 16S rRNA 5-GAGTATGCTCGCAAGAGTG-3
16S 993R 16S rRNA 5-CGTTGTTCGGGATTATTG-3
16S 1060F 16S rRNA 5-TCATCACTTTGTCATTTC-3
16S 1538R 16S rRNA 5-AAATAACGAAGAGTTTGATCC-3
BB425 3F 16S rRNA 5-GGAAGATGAGAGAAGGGAAG-3
BB426 288F 16S rRNA 5-AGGATTCGCCTTTGCCAAG-3
rpsG 58R rpsL (S12) 5-AATTATATCTGGTATCAACAAAAAC-3
rpsL U106F rpsL (S12) 5-AAAATTAAAGTTAGTGAAAATATCG-3
TABLE 2. Antibiotic susceptibilities and growth rates of the
B. burgdorferi wild-type strain B31–A and
antibiotic-resistant mutants
Strain Mutation
IC50 (g ml1) of the
following antibiotica: Doubling
time (h)b
SPT STR KAN GEN
B31–A None 0.22 11 9 2.5 7.9  0.5
DCSPR3 16S rRNA
C1186U
300 6 17 2.5 8.1  0.3
DCSPR6 16S rRNA
A1185G
500 9 13 2.5 8.1  0.1
DCKAN3 16S rRNA
A1402G
0.12 6 800 600 8.8  0.6
DCSmR3 S12 K88R 0.10 80 13 1.5 ND
DCSmR4 S12 K88E 0.08 110 16 1.5 8.0  0.2
a SPT, spectinomycin; STR, streptomycin; KAN, kanamycin; GEN, gentamicin.
b Values are means  standard errors of the means for three independent exper-
iments with a total of five replicates. ND, not determined.
TABLE 3. Frequency of spectinomycin-resistant
mutants in strain B31–A
Spectinomycin
concn (g ml1)
No. of cells
plated
No. of
colonies
Frequency
(106)
1.5 108 572  83a 5.7
107 69  22a 6.9
6.0 108 694  126a 6.9
107 62  21a 6.2
30 108 514  118b 5.1
107 62  5a 6.2
a Values are means  standard errors of the means for four independent exper-
iments.
b Value is the mean  standard error of the mean for seven independent
experiments.
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and DCSPR4, had a C1186U mutation in 16S rRNA. The
C1186U spectinomycin resistance mutation is homologous to the
site identified in spectinomycin-resistant E. coli and Salmonella
enterica (40, 47, 60), while the A1185G mutation is homologous
to that found in chloroplasts of C. reinhardtii (28) and has only
recently been identified in bacteria (5). There were no com-
pensatory mutations at the cross-helix partners G1057 (1186)
and U1058 (1185), which correspond to E. coli sites G1064 and
U1065. Mutations in the rpsE gene, encoding ribosomal pro-
tein S5, are also known to confer resistance to spectinomycin
(7, 23, 68). This gene was sequenced for our spectinomycin-
resistant isolates, and no mutations were found.
Antibiotic susceptibilities of spectinomycin-resistant mutants.
Susceptibility assays with DCSPR3 (C1186U) and DCSPR6
(A1185G) revealed that both mutations confer a high level of
resistance to spectinomycin. The IC50 of spectinomycin for
wild-type B. burgdorferi strain B31–A is 0.2 g ml1. For the
C1186U mutant, DCSPR3, the IC50 is 300 g ml
1, repre-
senting at least a 1,000-fold increase in resistance to spectino-
mycin. The spectinomycin IC50 is 500 g ml
1 for the
A1185G mutant, DCSPR6, which is thus 2,000 times more
resistant than the wild type (Table 2).
DCSPR3 and DCSPR6 did not have high levels of cross-
resistance to the aminoglycosides streptomycin, kanamycin,
and gentamicin (Table 2). The IC50s of streptomycin, kanamy-
cin, and gentamicin for the wild-type B. burgdorferi strain
B31–A were 11 g ml1, 9 g ml1, and 2.5 g ml1, respec-
tively, nearly identical to those reported previously (18). Ami-
noglycoside susceptibilities of DCSPR3 and DCSPR6 were
within twofold of those of the parental strain B31–A (Table 2).
Frequency and identification of aminoglycoside-resistant
mutants. The high frequency of spectinomycin-resistant mu-
tants identified in our studies motivated us to examine the
frequency and mechanism of resistance to closely related amino-
glycoside antibiotics. The maintenance of spectinomycin-resis-
tant mutants at high frequency indicates that there is a low
fitness cost for these mutants. The structurally similar amino-
glycosides were tested to determine if there is a corresponding
fitness cost associated with these mutations. Identifying the
frequency and levels of resistance of these mutants may also
aid in choosing reliable selectable markers for genetic manip-
ulation or clinical treatment of B. burgdorferi. Already, several
markers have been constructed with aminoglycoside resistance
cassettes (9, 16, 18, 58).
The frequency of kanamycin resistance was determined by
plating 108 or 109 cells of B. burgdorferi strain B31–A on semi-
solid BSK medium containing 40 g ml1 kanamycin. Colonies
appeared on kanamycin plates in 14 days, 3 days later than the
appearance of spectinomycin-resistant colonies. The frequency
of kanamycin-resistant mutants was between 1.3  108 and
1.4  107 (Table 4). Plating of 109 cells of B31–A on 30-g
ml1 gentamicin plates yielded similar results: the frequency of
gentamicin-resistant mutants was 1  108 (Table 4).
To determine the location of the mutation that conferred
resistance to kanamycin and gentamicin, three colonies were
isolated from kanamycin plates and one colony from a genta-
micin plate. Sequencing of the 16S rRNA gene from all four of
the clones revealed an A1402G mutation (Table 2), homolo-
gous to an A1408G mutation in E. coli (15, 50). The kanamy-
cin-resistant clone DCKAN3 represents both the kanamycin-
resistant mutants and the gentamicin-resistant mutant in
further studies, because they have the same 16S rRNA mu-
tation.
The frequency of streptomycin resistance is 2.0  108 to
3.4  109, based on the number of colonies that grew on
BSK plates containing 36 g ml1 of streptomycin (Table 4).
Colonies appeared within 11 days after plating. Sequence anal-
ysis of four streptomycin-resistant mutants revealed two differ-
ent mutations in the rpsL gene, encoding the S12 protein. An
A263G rpsL mutation in DCSmR3 resulted in a K88R substi-
tution in the S12 protein, and an A262G mutation resulted in
a K88E substitution in DCSmR4 (Table 2). Complete sequenc-
ing of the 16S rRNA gene on both strands revealed no 16S rRNA
mutations in these streptomycin-resistant strains.
Antibiotic susceptibilities of aminoglycoside-resistant mu-
tants. The DCKAN3 mutant was assayed for susceptibility to
kanamycin and the other antibiotics. The IC50 of kanamycin
was 800 g ml1, more than 90 times the wild-type IC50
(Table 2). The kanamycin-resistant mutant was, as expected,
cross-resistant to gentamicin at high levels. The IC50 of genta-
micin for this A1402G mutant (DCKAN3) was 600 g ml1,
indicating that it is 240-fold more resistant than wild-type
B31–A (Table 2). The A1402G mutation provides no resis-
tance to spectinomycin or streptomycin (Table 2).
The two streptomycin-resistant rpsL mutations conferred
slightly different levels of resistance to streptomycin (Table 2).
The IC50s were 80 g ml
1 for the K88R mutant (DCSmR3)
and 110 g ml1 for the K88E mutant (DCSmR4), which are
thus 7-fold and 10-fold more resistant, respectively, than the
wild type. Both of these streptomycin-resistant mutants had
small increases in susceptibility to spectinomycin and gentami-
cin (Table 2).
Fitness of spectinomycin- and aminoglycoside-resistant mu-
tants. The frequency of spectinomycin-resistant mutants in the
B31–A population was approximately 100-fold higher than the
frequency of the aminoglycoside-resistant mutants. We hy-
pothesized that this difference was a result of a lower fitness
cost of the 16S rRNA C1186U (DCSPR3) and A1185G
(DCSPR6) mutations conferring spectinomycin resistance.
This lower fitness cost enables spectinomycin-resistant mutants
to compete with wild-type B31–A and to be maintained at
frequencies higher than the typical mutation frequency ob-
TABLE 4. Frequency of aminoglycoside-resistant mutants
in strain B31–A
Antibiotic
(g ml1)
No. of cells
plated
No. of
colonies Frequency
Kanamycin (40) 109 13.2  4.3a 1.3  108
108 14.0  6.0b 1.4  107
Streptomycin (36) 109 3.4  1.7a 3.4  109
108 2.0  1.0a 2.0  108
Gentamicin (30) 109 10.3  1.2c 1.0  108
a Values are means  standard errors of the means for five independent exper-
iments.
b Value is the mean  standard error of the mean for four independent
experiments.
c Value is the mean  standard error of the mean for three independent
experiments.
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served for most bacteria (1, 35–37). To test this hypothesis,
growth and competition assays were performed with B31–A
and four of the mutants.
There were no statistically significant differences in the
growth rates of the mutants and wild-type B31-A (Table 2),
although DCKAN3 grew modestly slower than the other
strains. The doubling time for B31-A was calculated as 7.9 h,
while the doubling times were 8.8 h for DCKAN3 (P 	 0.30),
8.1 h for DCSPR3 (P 	 0.53) and DCSPR6 (P 	 0.77), and
8.0 h for DCSmR4 (P 	 0.96).
At the start of each competition assay, approximately 103
cells from each culture were plated to estimate the percentage
of antibiotic-resistant mutant cells and B31–A wild-type cells in
the competition cocultures. The number of colonies on plates
without antibiotic selection compared to plates with selection
indicated that there were approximately equal numbers of mu-
tant and wild-type cells (data not shown). Comparison of the
percentage of colonies that grew with selection at the begin-
ning of the assay and the percentage of colonies that grew with
selection at the end of the assay indicated that streptomycin-
resistant and kanamycin/gentamicin-resistant mutants (DCSmR4
and DCKAN3) were completely outgrown between 50 and
100 generations, while the spectinomycin-resistant mutants
(DCSPR3 and DCSPR6) were still present at 100 genera-
tions (Table 5).
The spectinomycin-resistant mutants cultured with B31–A
fared much better than the aminoglycoside-resistant mutants,
surviving in the population for 100 generations. Comparison of
the numbers of cells from the B31–A-plus-DCSPR3 cocultures
plated with selection versus no selection indicated that 18% of
the cells remaining after 100 generations were DCSPR3. Since
there is no selection for wild-type B31–A or against spectino-
mycin-resistant cells on the plates without spectinomycin, a test
was designed to assess the percentage of colonies that were
spectinomycin resistant on the plates without antibiotic.
Twenty colonies from a plate containing B31–A plus DCSPR3
with no selection were isolated and grown in liquid BSK-H
with 30 g ml1 of spectinomycin. The results of this experi-
ment were similar to that of the experiment comparing the
number of colonies on semisolid medium with selection versus
no selection: 4 of the 20 colonies (20%) were spectinomycin
resistant. Similar, but lower, numbers were also obtained for
the coculture of B31–A plus DCSPR6. Comparison of the
number of colonies on spectinomycin plates versus the number
of colonies on plates without spectinomycin indicated that 8%
of the cells in the coculture were resistant to spectinomycin
(DCSPR6) after 100 generations. Isolating 20 B31–A-plus-
DCSPR6 colonies from plates with no selection and growing
them in liquid BSK-H with 30 g ml1 of spectinomycin pro-
duced two spectinomycin-resistant wells, suggesting that 10%
of the colonies from the coculture were still spectinomycin
resistant (DCSPR6) after 100 generations. The experiment at
50 generations had more spectinomycin-resistant mutants
present than that at 100 generations. Plating with and without
selection showed that 41% of the cells were spectinomycin-
resistant mutants in both the B31–A-plus-DCSPR3 and the
B31–A-plus-DCSPR6 cocultures (Table 5).
No colonies from the coculture of B31–A plus DCKAN3
grew on plates with kanamycin, and no colonies from the
coculture of B31–A plus DCSmR4 appeared on plates with
streptomycin after 100 generations. However, colonies from
the same cultures grew on plates with no selection, indicating
that wild-type B31–A was the only cell type in the culture.
Plating of the B31–A-plus-DCSmR4 coculture at 50 genera-
tions did produce colonies on the streptomycin plates. Inde-
pendent experiments produced similar results, indicating that
6% of the cells in the B31–A-plus-DCSmR4 coculture were
DCSmR4 at 50 generations of the competition assay. Less than
1% of the cells in the B31–A-plus-DCKAN3 coculture were
DCKAN3 mutants at 50 generations (Table 5).
Single cultures used as controls for the competition assays
revealed that each of the mutant strains, DCSPR3, DCSPR6,
DCSmR4, and DCKAN3, grew on plates with and without
antibiotic selection after 100 generations, indicating that these
cells were still viable and antibiotic resistant (data not shown).
DISCUSSION
The high frequency of antibiotic-resistant colonies appear-
ing upon spectinomycin selection (18) prompted an investiga-
tion to identify mutations responsible for resistance. We hy-
pothesized that mutations in the 16S rRNA or small ribosomal
subunit proteins were the cause of spectinomycin resistance (3,
7, 10, 23, 26, 40, 47, 60) and that the high frequency of these
mutants in the B. burgdorferi B31–A population was due either
to a high mutation rate or to a low fitness cost (1, 37). We have
identified five different mutations conferring resistance to
spectinomycin, streptomycin, kanamycin, and gentamicin; the
spectinomycin-resistant mutants have a lower fitness cost than
the aminoglycoside-resistant mutants.
Spectinomycin resistance. Mutations at several sites includ-
ing 1191 to 1193 in the 16S rRNA of E. coli, S. enterica, C.
reinhardtii, and Chlamydia psittaci have been shown to confer
resistance to spectinomycin (5, 10, 28, 40, 47, 60). We have
identified an A1185G mutation and a C1186U mutation in
Borrelia burgdorferi 16S rRNA (nucleotide positions homolo-
gous to E. coli A1191 and C1192) that confer high levels of
resistance to spectinomycin (Table 2). The 1,300-fold increase
in resistance to spectinomycin due to the C1186U mutation is
similar to the resistance levels reported for a homologous
mutant of S. enterica (47). Perhaps of more interest is the
A1185G mutation, which confers over 2,200-fold resistance to
spectinomycin, since it has only recently been described in a
bacterium (5). A homologous mutation, which confers a high
TABLE 5. Competition of antibiotic-resistant strains
with the wild type
Strain
% of antibiotic-resistant colonies at:
50 generations 100 generations
B31–A  DCSPR3 41  4.4a (DCSPR3) 18  4.4b (DCSPR3)
B31–A  DCSPR6 41  2.1a (DCSPR6) 8  3.1b (DCSPR6)
B31–A  DCSmR4 6.0  2.0c (DCSmR4) 0  0c (DCSmR4)
B31–A  DCKAN3 0.75  0.25c (DCKAN3) 0  0c (DCKAN3)
a Values are means  standard errors of the means for three independent exper-
iments.
b Values are means  standard errors of the means for four independent
experiments.
c Values are means  standard errors of the means for five independent
experiments.
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level of resistance to spectinomycin, has been identified in the
chloroplast of the eukaryote C. reinhardtii (A1123G) (28).
Sequencing of the 16S rRNA gene revealed no other muta-
tions including the complementary nucleotides 1057 and 1058
(E. coli nucleotides 1063 and 1064). In addition, no mutations
were found in the rpsE gene encoding the S5 protein, a site of
spectinomycin resistance mutations in other bacteria (7, 23,
68). Secondary mutations in E. coli have been shown to confer
spectinomycin dependence when more than one mutation oc-
curs in the small ribosomal subunit involving S4 or S5 proteins
(13). Bacillus subtilis also appears to be spectinomycin depen-
dent when double mutations occur in the ribosomal genes
(29). This lack of dependence was confirmed by the ability of
DCSPR3 and DCSPR6 to grow in the absence of spectinomy-
cin (data not shown).
Mutants DCSPR6 (A1185G) and DCSPR3 (C1186U) had
the same susceptibility to gentamicin as wild-type B31–A.
However, both of these spectinomycin-resistant mutants were
slightly more susceptible to streptomycin and slightly more
resistant to kanamycin (Table 2). These minor differences in
aminoglycoside susceptibilities may be a result of small con-
formational changes along the 16S rRNA that affect the bind-
ing of streptomycin and kanamycin to the 16S rRNA.
The frequency of the spectinomycin-resistant phenotype in-
cludes both the C1186U and A1185G mutations; the frequency
of individual mutations was not determined. Additional point
mutations in the 16S rRNA gene, which have been identified in
other organisms as conferring spectinomycin resistance (5, 10,
26, 28, 65), may contribute to the phenotypic mutation rate as
well but were not represented in the seven mutants sequenced.
The concentration of spectinomycin (1.5 to 30 g ml1) and
the number of B31–A cells plated (107 or 108) did not affect the
frequency of mutants (Table 3). The frequency of spectino-
mycin-resistant mutants is considerably higher than the fre-
quencies of the aminoglycoside-resistant B. burgdorferi mutants
also reported in this study (Table 4) and the spectinomycin-
resistant mutation frequencies reported for most other bacte-
ria. Spectinomycin-resistant mutants appear at frequencies of
2  109 in E. coli (35), 3  108 in Salmonella enterica serovar
Enteritidis (35), and 108 in Mycoplasma mycoides (36), al-
though the frequency for C. psittaci is higher, at 5  105 (5).
DCSPR3 and DCSPR6 were able to compete with B31–A
better than either of the aminoglycoside-resistant mutants
DCSmR4 or DCKAN3. The high frequency of the spectino-
mycin-resistant mutants (6  106) compared to the aminogly-
coside-resistant mutants in the B31–A population is likely the
result of a lower fitness cost associated with these mutations (1,
37). This lower fitness cost probably indicates that the specti-
nomycin-resistant ribosomes function with efficiency compara-
ble to wild-type ribosomes. Sartakova et al. reported that B.
burgdorferi was considerably more susceptible to spectinomycin
in liquid medium than in semisolid medium (58). Our data
suggest that this difference was due to the greater number of
spirochetes assayed on semisolid medium (1  108 compared
to 2  105), which revealed the subpopulation of spectinomy-
cin-resistant mutants.
Kanamycin and gentamicin resistance. Resistance to the
aminoglycosides kanamycin and gentamicin in E. coli is con-
ferred as a result of U1406A or A1408G mutations in 16S
rRNA that reduce the binding affinity of the antibiotic for helix
44 (50, 51). We have identified an A1402G mutation in B.
burgdorferi strain B31–A conferring high levels of resistance to
kanamycin and gentamicin (Table 2). High levels of resistance
to kanamycin and gentamicin are also found in E. coli with the
homologous A1408G mutation (15, 43, 50) and Mycobacterium
tuberculosis with the homologous A1400G mutation (64). Sus-
ceptibility to the antibiotics spectinomycin and streptomycin
was slightly increased with the A1402G mutation (Table 2).
The frequencies of kanamycin-resistant mutants and strepto-
mycin-resistant mutants depended on the number of cells
plated (Table 4), which was not the case with spectinomycin-
resistant mutants (Table 3). We do not know the reason for
this but assume that it is an artifact of the plating technique,
which requires concentrating a culture to yield 109 cells.
Streptomycin resistance. Mutations at several sites in the
16S rRNA gene and the rpsL gene encoding S12 have been
identified as conferring resistance to streptomycin in many
organisms. We have identified two mutations in the B. burg-
dorferi rpsL gene conferring resistance to streptomycin. These
mutations at codon 88 encode K88R and K88E amino acid
substitutions in the ribosomal S12 protein. The frequency of
the streptomycin-resistant mutations (Table 4), which includes
both the K88R (DCSmR3) and K88E (DCSmR4) mutations, is
in agreement with previous reports for other bacteria. The
mutation frequency for the rpsL gene is 108 in Mycobacte-
rium smegmatis (61), 4  1010 in E. coli (38), and 107 in
T. thermophilus (27). The frequency of the K88R and K88E
mutants is similar to that of the kanamycin-resistant mutants
and 100-fold less than that of the spectinomycin-resistant mu-
tants in B. burgdorferi.
Neither mutant exhibited any of the characteristics associ-
ated with streptomycin dependence. Complete sequencing of
the rpsL and 16S rRNA genes revealed no secondary muta-
tions associated with streptomycin dependence. Another char-
acteristic of this phenotype is increased resistance to kana-
mycin and gentamicin. Although the level of resistance to
kanamycin did increase slightly, the DCSmR4 mutant was able
to grow on semisolid medium without streptomycin, and resis-
tance to gentamicin decreased slightly, which is not consistent
with the streptomycin-dependent phenotype.
The resistance levels for DCSmR3 (7-fold) and DCSmR4
(10-fold) are much lower than those for DCSPR3, DCSPR6,
and DCKAN3, which are all 100-fold more resistant to the
respective antibiotics used to select them (Table 2). The levels
of resistance in B. burgdorferi are typical of those of other
streptomycin-resistant mutants. Similar susceptibilities have
been identified in M. smegmatis mutants that have the homol-
ogous mutations in rpsL as well as in 16S rRNA (61). The slight
differences in streptomycin resistance between DCSmR3 (the
conservative K88R substitution) and DCSmR4 (K88E) may be
the result of the change in the charge at this position in the S12
protein.
DCSmR4 was unable to compete with wild-type B31–A,
indicating a significant fitness cost for this mutation (Table 5).
S12 mutations have been shown to affect the selection of cog-
nate tRNAs and the rates of polypeptide chain elongation in E.
coli and T. thermophilus, which may be the source of this fitness
cost (34, 51). Mutations in the E. coli rpsL gene slow the rates
of polypeptide chain elongation by nearly 20% (34). A lower
rate of translation could explain the inability of DCSmR4 to
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compete with wild-type B31–A. Conversely, spectinomycin-re-
sistant mutations have been shown to have little if any effect on
ribosome function even in the absence of antibiotic (10, 40),
although recently some synergistic and antagonistic effects
were demonstrated when additional mutations were combined
with the C1192U spectinomycin resistance mutation in E. coli
(52). Recently described spectinomycin-resistant mutants of C.
psittaci demonstrated significant decreases in fitness (4). No-
tably, the C. psittaci C1192U mutant was more fit than the
A1191G mutant, which is similar to our data with B. burgdorferi
(Tables 2 and 5).
Antibiotic resistance as a selectable marker. Although none
of the antibiotics in this study are used clinically to treat Lyme
disease, resistance to aminoglycosides has been employed as a
selectable marker for genetic manipulation of the spirochete
(9, 16, 18, 58). We have found that a large subpopulation of
spectinomycin-resistant B. burgdorferi strain B31–A prevents
functional selection of the recombinant aadA cassette (18) with
spectinomycin. More selectable markers are needed for in-
creasingly sophisticated genetic experiments with the Lyme
disease agent (53); the caveat regarding the frequency of back-
ground mutants resistant to an antibiotic should be considered
prior to developing candidate genetic markers.
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P. Sander. 2001. Mechanisms of streptomycin resistance: selection of muta-
tions in the 16S rRNA gene conferring resistance. Antimicrob. Agents Che-
mother. 45:2877–2884.
62. Steere, A. C. 2001. Lyme disease. N. Engl. J. Med. 345:115–125.
63. Strigini, P., and L. Gorini. 1970. Ribosomal mutations affecting efficiency of
amber suppression. J. Mol. Biol. 47:517–530.
64. Suzuki, Y., C. Katsukawa, A. Tamaru, C. Abe, M. Makino, Y. Mizuguchi,
and H. Taniguchi. 1998. Detection of kanamycin-resistant Mycobacterium
tuberculosis by identifying mutations in the 16S rRNA gene. J. Clin. Micro-
biol. 36:1220–1225.
65. Svab, Z., and P. Maliga. 1991. Mutation proximal to the tRNA binding
region of the Nicotiana plastid 16S rRNA confers resistance to spectinomy-
cin. Mol. Gen. Genet. 228:316–319.
66. Terekhova, D., M. L. Sartakova, G. P. Wormser, I. Schwartz, and F. C.
Cabello. 2002. Erythromycin resistance in Borrelia burgdorferi. Antimicrob.
Agents Chemother. 46:3637–3640.
67. Wallace, B. J., P.-C. Tai, and B. D. Davis. 1974. Selective inhibition of
initiating ribosomes by spectinomycin. Proc. Natl. Acad. Sci. USA 71:1634–
1638.
68. Wilcox, S. K., G. S. Cavey, and J. D. Pearson. 2001. Single ribosomal protein
mutations in antibiotic-resistant bacteria analyzed by mass spectrometry.
Antimicrob. Agents Chemother. 45:3046–3055.
452 CRISWELL ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on S
eptem
ber 17, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
